Previous 10 | Next 10 |
2023-12-29 15:30:56 ET More on Inspire Medical Systems Inspire Medical Systems: Time To Wake Up Inspire Medical Systems, Inc. (INSP) Q3 2023 Earnings Call Transcript Inspire Medical Systems, Inc. 2023 Q3 - Results - Earnings Call Presentation Inspire Medical ...
Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual Meeting PR Newswire – NKTR-255 Combination Expanded NK Cells and Enhanced ADCC Against Rituximab-...
2023-11-25 16:32:53 ET More on BioCryst Pharmaceuticals, Crinetics Pharmaceuticals, etc. Mirum Pharmaceuticals, Inc. (MIRM) Q3 2023 Earnings Call Transcript BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2023 Earnings Call Transcript Immunocore: First Half Of 2024 IMC-F106...
2023-11-07 21:11:10 ET Nektar Therapeutics (NKTR) Q3 2023 Earnings Conference Call November 07, 2023, 05:00 PM ET Company Participants Vivian Wu - Director, IR and Corporate Affairs Howard Robin - President and CEO Jonathan Zalevsky - Chief, Research and Developm...
2023-11-07 16:19:10 ET More on Nektar Therapeutics Nektar in collaboration to evaluate non-small cell lung cancer candidate Seeking Alpha’s Quant Rating on Nektar Therapeutics Historical earnings data for Nektar Therapeutics Financial information for N...
Nektar Therapeutics Reports Third Quarter 2023 Financial Results PR Newswire SAN FRANCISCO , Nov. 7, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2023 . Cash...
Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...
Nektar Therapeutics (NKTR) is expected to report $-0.18 for Q3 2023
Nektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial Markets PR Newswire SAN FRANCISCO , Oct. 31, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial resu...
Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress PR Newswire – Dose-Dependent Efficacy Reported Across All Endpoints for REZPEG Demonstrating a Rap...
News, Short Squeeze, Breakout and More Instantly...
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference PR Newswire SAN FRANCISCO ,...
Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata PR Newswire SAN FRANCISCO , March 5, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a biotechnology c...
Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported preliminary fourth-quar...